171 related articles for article (PubMed ID: 23752433)
1. Patent portfolios for biotech inventions.
Wang SJ
Nat Biotechnol; 2013 Jun; 31(6):501-3. PubMed ID: 23752433
[No Abstract] [Full Text] [Related]
2. Patent law protection of inventions in medicine and pharmaceutical industry.
Miladinović Z; Varga S; Radojković M
Vojnosanit Pregl; 2013 Jun; 70(6):600-5. PubMed ID: 23885528
[No Abstract] [Full Text] [Related]
3. Don't feed the trolls.
Nature; 2014 Jun; 510(7503):7. PubMed ID: 24910865
[No Abstract] [Full Text] [Related]
4. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
5. Patent portfolio management: literature review and a proposed model.
Conegundes De Jesus CK; Salerno MS
Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
[TBL] [Abstract][Full Text] [Related]
6. At a glance: the European patent with unitary effect.
Höpfner S
Pharm Pat Anal; 2016 Sep; 5(5):295-300. PubMed ID: 27531460
[TBL] [Abstract][Full Text] [Related]
7. Must an inventor "possess" an invention to patent it?
Woessner WD; Chadwick RA
Cold Spring Harb Perspect Med; 2014 Sep; 4(11):a020867. PubMed ID: 25237144
[TBL] [Abstract][Full Text] [Related]
8. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
Jannuzzi AH; Vasconcellos AG; de Souza CG
Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
[TBL] [Abstract][Full Text] [Related]
9. Impact of America Invents Act on Biotech Intellectual Property.
Murphy A; Stramiello M; Stroud J; Lewis S; Irving T
Cold Spring Harb Perspect Med; 2015 Apr; 5(9):a020784. PubMed ID: 25918182
[TBL] [Abstract][Full Text] [Related]
10. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
Dhulap S; Kulkarni M
Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
[TBL] [Abstract][Full Text] [Related]
11. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
12. A Career in Patent Law: At the Cutting Edge of Science, but Not at the Bench.
Mamajiwalla S
Cold Spring Harb Perspect Biol; 2018 Jul; 10(7):. PubMed ID: 29967011
[TBL] [Abstract][Full Text] [Related]
13. Inventions and Patents: A Practical Tutorial.
Mehta H; Tidwell L; Liotta LA
Methods Mol Biol; 2017; 1606():379-397. PubMed ID: 28502014
[TBL] [Abstract][Full Text] [Related]
14. Teva v. AstraZeneca and secret prior art under 102(g)(2).
Lee S; Knierim M
Nat Biotechnol; 2012 Sep; 30(9):831-3. PubMed ID: 22965051
[No Abstract] [Full Text] [Related]
15. Which patent and where? Why international patent transparency by companies is needed for medicines.
Beall RF; Attaran A
Nat Biotechnol; 2016 Sep; 34(9):923-6. PubMed ID: 27606455
[No Abstract] [Full Text] [Related]
16. Panel rules against Canada on patent terms for pre-TRIPS patents.
Elliott R
Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):43, 45. PubMed ID: 11833196
[TBL] [Abstract][Full Text] [Related]
17. Inherent Anticipation in the Pharmaceutical and Biotechnology Industries.
Goldman M; Evans G; Zappia A
Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021006. PubMed ID: 25877394
[TBL] [Abstract][Full Text] [Related]
18. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
Garber K
Science; 2006 May; 312(5775):827. PubMed ID: 16690824
[No Abstract] [Full Text] [Related]
19. Patent quality.
Sklan A
Pharm Pat Anal; 2014 Jan; 3(1):17-24. PubMed ID: 24354975
[TBL] [Abstract][Full Text] [Related]
20. Myriad diagnostic concerns.
Nat Biotechnol; 2013 Jul; 31(7):571. PubMed ID: 23839123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
